Trial Profile
A phase II trial of sorafenib in BAC or never-smokers with any lung adenocarcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 09 Mar 2010 Actual patient number (5) added as reported by ClinicalTrials.gov.
- 09 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Mar 2010 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.